AC BioScience is focused on personalized molecular therapies; that is, medical care designed to optimize efficiency or therapeutic benefit for particular groups of patients by using molecular profiling.
We bring to clinical validation unique scientific discoveries identified by our co-founder to dramatically impact the efficacy of cancer treatment therapies. Clinical trials are scheduled to start for two of its proprietary molecules in 2022.
The company develops novel uses for existing molecules with well-established safety and tolerance profiles. Our compound for tumor vascular normalization has a history of FDA-approved Phase 1 data in a different application
To maximize resources and ensure sustainability, the company operates with a lean organization. This is possible through the deep involvement of the two co-founders in strategic and scientific development and operations, and the obtainment of research grants. Drug development and clinical validation are outsourced to specialist companies or academic institutions.
For one of its molecules, the company is challenging the traditional antiangiogenic approach to cancer therapy. Our neo-adjuvant therapy is designed to improve the efficacy of all types of chemo- and radiotherapy for solid tumors.
One of our new molecules (ACB1801) also holds promise, within immune-oncology, to induce F-actin network remodeling and thereby potentiate the therapeutic benefit of anti-PD-1.
The company’s initial targets are the treatment of tumoral and immunological pathologies.
One of our projects aims to improve the efficacy of chemo- and radiotherapy in the treatment of solid tumors, using sphingosine-1-phosphate (S1P) metabolism modulators as tumor vascular normalizers.
A Beta-carboline derivative (ACB1801) has successfully undergone pre-clinical testing, the goal of which was to revert the tumor phenotype and thereby enhance the efficacy of checkpoint-inhibitor immune therapy.
The company has also acquired a patent for an antitumor cationic amphipathic peptide (CAP6). It belongs to a new generation of cancer drugs with limited side effects and generally greater efficacy.
Our “success by design” business model starts with the identification of new medical strategies for the treatment of cancer.
AC BioScience’s objective is to turn innovation into economic value and to secure optimum protection for its intellectual property. To this end, the company has been diligently protecting its innovations, research and validation work by filing patent applications or acquiring patents for their broadest applications.
AC BioScience has obtained a EUROSTARS grant of € 852 Thousand in 2022 for its multi-partner transnational innovation project. AC BioScience is the lead partner of a consortium that includes the Luxembourg Institute of Health (LIH) and Gustave Roussy Institute (IGR, France). This European grant will allow AC BioScience to accelerate the preclinical development of its immuno-stimulatory lead molecule ACB1801.
Additional joint research projects with LIH and IGR are on-going in the field of immuno-oncological studies for CRC, and combination treatments of S1P metabolism modulators and radiotherapy.
A research agreement has been concluded with the Institut Curie in Paris to test the effectiveness of our S1P modulators in TNBC and HCC.
An Innosuisse-funded collaborative research project with the Biochemistry Group of the University of Lausanne has started in June 2020. The goal of the project is to demonstrate that the administration of immuno-modulating compounds can be used to overcome parasite-elicited immune subversion to treat certain infectious diseases.